These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 20739041

  • 21. [Parkinson's disease: psychological and behavioral disorders].
    Delgadillo-Iniguez D, Corvol JC, Gély-Nargeot MC, Lacomblez L.
    Psychol Neuropsychiatr Vieil; 2006 Dec; 4 Spec No 1():S11-6. PubMed ID: 23631043
    [Abstract] [Full Text] [Related]

  • 22. Nonmotor symptoms in Parkinson's disease: expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic problem.
    Sung VW, Nicholas AP.
    Neurol Clin; 2013 Aug; 31(3 Suppl):S1-16. PubMed ID: 23931951
    [Abstract] [Full Text] [Related]

  • 23. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R, Aharon-Peretz J, Tsitrinbaum Z.
    Neuropsychologia; 2007 Jan 28; 45(2):357-67. PubMed ID: 16876208
    [Abstract] [Full Text] [Related]

  • 24. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK.
    Arch Neurobiol (Madr); 1991 Jan 28; 54(6):282-7. PubMed ID: 1687430
    [No Abstract] [Full Text] [Related]

  • 25. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P, Vécsei L.
    Ideggyogy Sz; 2007 Jan 20; 60(1-2):61-4. PubMed ID: 17432097
    [Abstract] [Full Text] [Related]

  • 26. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
    Vale S.
    Exp Biol Med (Maywood); 2008 Aug 20; 233(8):941-51. PubMed ID: 18535172
    [Abstract] [Full Text] [Related]

  • 27. Intervening in the neuropsychiatric features of Parkinson's disease.
    Weintraub D, Stern MB.
    Expert Rev Neurother; 2007 Jun 20; 7(6):699-710. PubMed ID: 17563252
    [Abstract] [Full Text] [Related]

  • 28. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
    Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P.
    Brain; 2010 Apr 20; 133(Pt 4):1111-27. PubMed ID: 20237128
    [Abstract] [Full Text] [Related]

  • 29. [Drug therapy of Parkinson's disease].
    Myllylä V.
    Duodecim; 1997 Apr 20; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract] [Full Text] [Related]

  • 30. Therapy of Parkinson's disease: are we at the end of the road?
    Nag D.
    J Assoc Physicians India; 1992 Jun 20; 40(6):361-3. PubMed ID: 1360470
    [No Abstract] [Full Text] [Related]

  • 31. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease.
    Müller B, Assmus J, Larsen JP, Haugarvoll K, Skeie GO, Tysnes OB, ParkWest study group.
    Acta Neurol Scand; 2013 Apr 20; 127(4):290-4. PubMed ID: 22998158
    [Abstract] [Full Text] [Related]

  • 32. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO.
    MMW Fortschr Med; 2002 May 06; Suppl 2():37-43. PubMed ID: 12070848
    [Abstract] [Full Text] [Related]

  • 33. [The recent advance of treatment of Parkinson's disease].
    Matsubara E.
    Nihon Rinsho; 2004 Sep 06; 62(9):1725-8. PubMed ID: 15462392
    [Abstract] [Full Text] [Related]

  • 34. Cognitive, affective, and psychiatric features of Parkinson's disease.
    Barbas NR.
    Clin Geriatr Med; 2006 Nov 06; 22(4):773-96, v-vi. PubMed ID: 17000335
    [Abstract] [Full Text] [Related]

  • 35. [Addictions, drives and Parkinson's disease].
    Azulay JP.
    Rev Neurol (Paris); 2008 Apr 06; 164(4):308-9. PubMed ID: 18439922
    [No Abstract] [Full Text] [Related]

  • 36. Cognitive and behavioural impairment in Parkinson's disease.
    Merims D, Freedman M.
    Int Rev Psychiatry; 2008 Aug 06; 20(4):364-73. PubMed ID: 18925485
    [Abstract] [Full Text] [Related]

  • 37. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease.
    Devos D, Defebvre L, Bordet R.
    Fundam Clin Pharmacol; 2010 Aug 06; 24(4):407-21. PubMed ID: 20163480
    [Abstract] [Full Text] [Related]

  • 38. Clinical practice. Diagnosis and initial management of Parkinson's disease.
    Nutt JG, Wooten GF.
    N Engl J Med; 2005 Sep 08; 353(10):1021-7. PubMed ID: 16148287
    [No Abstract] [Full Text] [Related]

  • 39. The relation of testosterone levels with fatigue and apathy in Parkinson's disease.
    Kenangil G, Orken DN, Ur E, Forta H, Celik M.
    Clin Neurol Neurosurg; 2009 Jun 08; 111(5):412-4. PubMed ID: 19131155
    [Abstract] [Full Text] [Related]

  • 40. [Apathy in Parkinson's disease: clinical features, mechanisms and assessment].
    Dujardin K, Defebvre L.
    Rev Neurol (Paris); 2012 Jun 08; 168(8-9):598-604. PubMed ID: 22926025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.